Converging pathways: shared brain circuitry engaged by monoaminergic antidepressants, ketamine and psilocybin
bioRxiv (Cold Spring Harbor Laboratory) May 30, 2025 Pavel Osten, K Sunny Joseph, Jane Collins et al. preprint
Abstract Ketamine has transformed depression treatment by providing therapeutic relief within a single day, unlike monoaminergic antidepressants that require weeks to take effect. Here, we conducted whole-brain screening in mice to compare drug-evoked c-fos expression—acting as a marker of brain activity leading to protein synthesis-dependent forms of plasticity—following treatment with...